Hepalink (9989) Schedules Board Meeting on October 30, 2025 to Review Third Quarterly Results

Bulletin Express

Oct 17

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Stock code: 9989) has announced that its board of directors will convene on October 30, 2025. The meeting will focus on reviewing and approving the company’s third quarterly results for the nine-month period ended September 30, 2025, as well as finalizing plans for their publication.

The announcement is dated October 17, 2025. According to the information disclosed, the executive directors of the company include Li Li, Li Tan, Shan Yu, and Zhang Ping, while the independent non-executive directors are Lu Chuan, Huang Peng, and Yi Ming.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179453281"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179453281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179453281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179453281","market":"hk","top_or_hot":-1,"title":"Hepalink (9989) Schedules Board Meeting on October 30, 2025 to Review Third Quarterly Results","media":"Bulletin Express","content":"<p>Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Stock code: 9989) has announced that its board of directors will convene on October 30, 2025. The meeting will focus on reviewing and approving the company’s third quarterly results for the nine-month period ended September 30, 2025, as well as finalizing plans for their publication.</p>\n<p>The announcement is dated October 17, 2025. According to the information disclosed, the executive directors of the company include Li Li, Li Tan, Shan Yu, and Zhang Ping, while the independent non-executive directors are Lu Chuan, Huang Peng, and Yi Ming.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hepalink (9989) Schedules Board Meeting on October 30, 2025 to Review Third Quarterly Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHepalink (9989) Schedules Board Meeting on October 30, 2025 to Review Third Quarterly Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-17 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Stock code: 9989) has announced that its board of directors will convene on October 30, 2025. The meeting will focus on reviewing and approving the company’s third quarterly results for the nine-month period ended September 30, 2025, as well as finalizing plans for their publication.</p>\n<p>The announcement is dated October 17, 2025. According to the information disclosed, the executive directors of the company include Li Li, Li Tan, Shan Yu, and Zhang Ping, while the independent non-executive directors are Lu Chuan, Huang Peng, and Yi Ming.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09989","symbol_name":"海普瑞","start_time":0,"source_url":"","article_id":"1179453281","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179453281","pubTimestamp":1760690438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Stock code: 9989) has announced that its board of directors will convene on October 30, 2025. The meeting will focus on reviewing and approving the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09989":"海普瑞"},"translate_title":"海普瑞(9989)定于2025年10月30日召开董事会审议第三季度业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1},"content_text":"Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Stock code: 9989) has announced that its board of directors will convene on October 30, 2025. The meeting will focus on reviewing and approving the company’s third quarterly results for the nine-month period ended September 30, 2025, as well as finalizing plans for their publication.\nThe announcement is dated October 17, 2025. According to the information disclosed, the executive directors of the company include Li Li, Li Tan, Shan Yu, and Zhang Ping, while the independent non-executive directors are Lu Chuan, Huang Peng, and Yi Ming.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}